Abstract
In a previous study, we found a positive association between premenopausal use of progestagens and breast cancer risk. We conducted the present study to assess the risk of breast cancers defined by their histology and hormone receptors status. We evaluated the association between progestagen-only intake (except for mini pills) before menopause and after the age of 40 years and invasive breast cancer risk in 67,057 women participating in the French E3N cohort study. Histologically confirmed invasive breast cancers (2,264) were identified through biennial self-administered questionnaires completed from 1992 to 2002. Risk estimates were calculated using the Cox proportional hazard model. We found an increased risk of lobular carcinoma associated with premenopausal use of progestagens among both current and past users [hazard raatio (HR), 1.51; 95% confidence interval (95% CI), 1.02-2.24 and HR, 1.38; 95% CI, 1.08-1.75, respectively]. Among current users, the use of progestagens for 4.5 years or more was associated with an increased risk of estrogen receptor-positive/progesterone receptor-positive carcinomas (HR, 1.68; 95% CI, 1.05-2.68), whereas current use of progestagens for
| Original language | English |
|---|---|
| Pages (from-to) | 2723-2728 |
| Number of pages | 6 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 17 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2008 |
Fingerprint
ASJC Scopus subject areas
- Epidemiology
- Oncology
Cite this
Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. / Fabre, Alban; Fournier, Agnès; Mesrine, Sylvie; Gompe, Anne; Desreux, Joëlle; Berrino, Franco; Boutron-Ruault, Marie Christine; Romieu, Isabelle; Clavel-Chapelon, Françoise.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 10, 10.2008, p. 2723-2728.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Progestagens use before menopause and breast cancer risk according to histology and hormone receptors
AU - Fabre, Alban
AU - Fournier, Agnès
AU - Mesrine, Sylvie
AU - Gompe, Anne
AU - Desreux, Joëlle
AU - Berrino, Franco
AU - Boutron-Ruault, Marie Christine
AU - Romieu, Isabelle
AU - Clavel-Chapelon, Françoise
PY - 2008/10
Y1 - 2008/10
N2 - In a previous study, we found a positive association between premenopausal use of progestagens and breast cancer risk. We conducted the present study to assess the risk of breast cancers defined by their histology and hormone receptors status. We evaluated the association between progestagen-only intake (except for mini pills) before menopause and after the age of 40 years and invasive breast cancer risk in 67,057 women participating in the French E3N cohort study. Histologically confirmed invasive breast cancers (2,264) were identified through biennial self-administered questionnaires completed from 1992 to 2002. Risk estimates were calculated using the Cox proportional hazard model. We found an increased risk of lobular carcinoma associated with premenopausal use of progestagens among both current and past users [hazard raatio (HR), 1.51; 95% confidence interval (95% CI), 1.02-2.24 and HR, 1.38; 95% CI, 1.08-1.75, respectively]. Among current users, the use of progestagens for 4.5 years or more was associated with an increased risk of estrogen receptor-positive/progesterone receptor-positive carcinomas (HR, 1.68; 95% CI, 1.05-2.68), whereas current use of progestagens for
AB - In a previous study, we found a positive association between premenopausal use of progestagens and breast cancer risk. We conducted the present study to assess the risk of breast cancers defined by their histology and hormone receptors status. We evaluated the association between progestagen-only intake (except for mini pills) before menopause and after the age of 40 years and invasive breast cancer risk in 67,057 women participating in the French E3N cohort study. Histologically confirmed invasive breast cancers (2,264) were identified through biennial self-administered questionnaires completed from 1992 to 2002. Risk estimates were calculated using the Cox proportional hazard model. We found an increased risk of lobular carcinoma associated with premenopausal use of progestagens among both current and past users [hazard raatio (HR), 1.51; 95% confidence interval (95% CI), 1.02-2.24 and HR, 1.38; 95% CI, 1.08-1.75, respectively]. Among current users, the use of progestagens for 4.5 years or more was associated with an increased risk of estrogen receptor-positive/progesterone receptor-positive carcinomas (HR, 1.68; 95% CI, 1.05-2.68), whereas current use of progestagens for
UR - http://www.scopus.com/inward/record.url?scp=54249091768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54249091768&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-08-0056
DO - 10.1158/1055-9965.EPI-08-0056
M3 - Article
VL - 17
SP - 2723
EP - 2728
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 10
ER -